pharma · Metastatic Prostate Cancer · Prostate Cancer · TLX
Telix Innovations
Telix Innovations is a pharma organization headquartered in Herstal, BE. It trades on NYSE under ticker TLX. Primary therapeutic focus areas include Metastatic Prostate Cancer, Prostate Cancer, Clear Cell Renal Cell Carc
Rue de Hermée 255, Herstal, Région wallonne 4040, BE HQ
2015 Founded
14 Employees
Public company Type
TLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Rue de Hermée 255, Herstal, Région wallonne 4040, BE
- Founded
- 2015
- Employees
- 14
- Programs
- 27
- Drugs
- 11
- Patents
- 3
89Zr-girentuximab
Phase 1 · other · Carcinoma, Renal Cell
89Zr-girentuximab for Carcinoma, Renal Cell is a Phase 1 program (other) at Telix Innovations with 1 ClinicalTrials.gov record(s).
Internal code 89Zr-TLX250-004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Telix Innovations
- Phase
- Phase 1
- Modality
- other
- Indication
- Carcinoma, Renal Cell
- Status
- completed
- Trials
- 1